Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone. Ixazomib is the first oral PI to be approved in routine practice but has not yet been e...

Descripción completa

Detalles Bibliográficos
Autores principales: Muchtar, Eli, Gertz, Morie A., LaPlant, Betsy R., Buadi, Francis K., Leung, Nelson, O’Brien, Patrick, Bergsagel, P. Leif, Fonder, Amie, Hwa, Yi Lisa, Hobbs, Miriam, Helgeson, Dania K., Bradt, Erin E., Gonsalves, Wilson, Lacy, Martha Q., Kapoor, Prashant, Siddiqui, Mustaqueem, Larsen, Jeremy T., Warsame, Rahma, Hayman, Suzanne R., Go, Ronald S., Dingli, David, Kourelis, Taxiarchis V., Dispenzieri, Angela, Rajkumar, S. Vincent, Kumar, Shaji K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631712/
https://www.ncbi.nlm.nih.gov/pubmed/35737873
http://dx.doi.org/10.1182/bloodadvances.2022007781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631712/
https://www.ncbi.nlm.nih.gov/pubmed/35737873
http://dx.doi.org/10.1182/bloodadvances.2022007781

Ejemplares similares